<DOC>
	<DOCNO>NCT03083743</DOCNO>
	<brief_summary>The trial evaluate efficacy safety recombinant human Apo-2 ligand treat patient advanced retreat non-small cell lung cancer</brief_summary>
	<brief_title>A Phase III Trial Recombinant Human Apo-2 Ligand Injection</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Age : 18 75 year old 2 . Pathologically diagnose advanced nonsmall cell lung cancer ( stage Ⅳ ) measurable lesion ( diameter tumor lesion display CT scan ≥ 10 mm ; short diameter lymph node lesion CT scan ≥ 15 mm ; radiotherapy , radiofrequency ablation local treatment give measurable lesion ) 3 . Patients negative EGFR ALK genesensitive mutation unknown status treatment failure recurrence previously undergoing treatment two chemotherapy regimen ( least one platinumcontaining twodrug regimen include ) 4 . Patients positive EGFRTKI ALKTKI genesensitive mutation treatment failure recurrence previously undergo one platinumcontaining chemotherapy regimen may include . Note treatment give neoadjuvant therapy phase consider part treatment regimen ; however , recurrence occur within 6 month end adjuvant therapy , adjuvant therapy consider part treatment regimen , within 6 month , adjuvant therapy consider part treatment regimen . The term `` treatment failure '' define : ( 1 ) progression present course treatment last treatment evidence definitive image clinical progression ; ( 2 ) patient withdrawn standard treatment due inability tolerate adverse event grade IV hematological toxicity , grade II nonhematological toxicity grade II major organ damage , heart , liver kidney accord NCICTCAE Version 4.0 . 5 . ECOG status 01 6 . Expected survival ≥ 3 month 7 . Patients recover damage cause treatment give ( ≤ grade 1 accord NCICTCAE version 4.0 ) ; interval nitrosourea mitomycin give ≥ 6 week ; interval cytotoxic drug , Avastin , radiotherapy surgery ≥ 4 week ; interval EGFR TKI molecular target drug ≥ 2 week 8 . Major organ function normally , e.g . follow criterion meet ( 1 ) Blood routine test shall comply criterion follow ( transfusion blood blood product within 14 day , correction GCSF hematopoietic stimulating factor ) : 1 . Hemoglobin（HB） ≥ 90 g/L 2 . Absolute neutrophil count（ANC） ≥ 1.5 × 10（9）/L 3 . Platelets（PLT ）≥ 80 × 10（9）/L ( 2 ) Biochemical test shall comply criterion follow : 1 . Total bilirubin（TBIL） &lt; 1.5 × upper limit normal（ULN） 2 . Alanine aminotransferase （ALT） aspartate aminotransferase（AST） &lt; 2.5 × ULN ; &lt; 5 × ULN patient liver metastases 3 . Serum Cr ≤ 1.25 × ULN endogenous creatinine clearance &gt; 45 ml / min ( CockcroftGault formula ) 9 . Female patient childbearing age must take reliable contraceptive measure receive pregnancy test ( either serum urine ) show negative result within 7 day inclusion willing take appropriate contraceptive measure trial follow 8 week last administration test drug . Male patient shall agree take appropriate contraceptive measure undergone surgical sterilization trial follow 8 week last administration test drug 10 . Subjects shall participate study , sign informed consent , good compliance , cooperate followup 1 . Small cell lung cancer ( include small cell carcinoma mixed nonsmall cell lung cancer ) 2 . Patients definitive history severe allergy biological product 3 . Patients active ( without medical control ) brain metastasis , cancer meningitis , spinal cord compression , brain leptomeninges disorder identify CT MRI examination inclusion process ( however , patient brain metastasis complete treatment 21 day prior randomization maintain symptomatic stability may include ) 4 . Patients Grade II myocardial ischemia myocardial infarction poorly control arrhythmia ( include male patient QTc interval ≥ 450 m female patient QTc interval ≥ 470 m ) 5 . Patients Grade III IV heart dysfunction accord NYHA leave ventricular ejection fraction ( LVEF ) &lt; 50 % identified cardiac ultrasound examination 6 . Patients persistent bradycardia positive result atropine test 7 . Patients diseases concern hemorrhagic tendency 8 . Dropsy serous cavity ( include pleural effusion , ascites , pericardial effusion ) present clinical symptom require medical treatment 9 . Patients active hepatitis B hepatitis C 10 . Patients active infection require antimicrobial treatment ( antibiotic , antiviral drug , antifungal drug ) 11 . Patients history psychotropic drug abuse failure get rid drug mental disorder 12 . Patients participate clinical trial regard antitumor drug within 4 week prior randomization 13 . Longterm user adrenal cortex hormone immunosuppressive agent 14 . Patients history suffer noncured malignancy , except cure skin basal cell carcinoma , cervical carcinoma situ superficial bladder cancer 15 . Pregnant breastfeeding woman ; fertile patient unwilling unable take effective contraceptive measure 16 . Patients positive skin test result injection recombinant human Apo2 ligand 17 . Other condition researcher consider may impact performance clinical trial interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Carcinoma , Bronchogenic</keyword>
	<keyword>Bronchial Neoplasms</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Antineoplastic Agents , Cytokines</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Biological activity factor</keyword>
	<keyword>Genetic Engineering</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>